Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data

Journal of Viral Hepatitis

Volumn 14, Issue 12, 2007, Pages 859-869

  Berenguer, J ^a   Bellon J M ^a   Miralles, P ^a   Alvarez E ^a   Sanchez Conde M ^a   Cosin J ^a   Lopez J C ^a   Alvarez F ^a   Catalan P ^a   Resino, S ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Biological markers blood; Diagnostic techniques; Digestive system; Hepatitis C chronic complications; Human deficiency virus infections complications; Liver cirrhosis diagnosis aetiology; Liver pathology

Indexed keywords

ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GLUCOSE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RANDOMIZATION; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT; VALIDATION PROCESS;

ADULT; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; PLATELET COUNT; PREDICTIVE VALUE OF TESTS;

EID: 36749072713     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00881.x     Document Type: Article

References (48)

1. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993 6 (6 602 610.
2. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994 87 (3 555 561.
3. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997 26 (1 1 5.
4. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001 33 (4 562 569.
5. Martinez-Sierra C, Arizcorreta A, Diaz F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003 36 (4 491 498.
6. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 (4 1054 1058.
7. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 (3 492 497.
8. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001 32 (8 1207 1214.
9. Soriano V, Puoti M, Sulkowski M et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004 18 (1 1 12.
10. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996 23 (6 1334 1340.
11. Forns X, Ampurdanes S, Sanchez-Tapias JM et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001 35 (2 265 271.
12. Health NIo National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002 5 (Suppl. 1 S3 S20.
13. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002 5 (Suppl. 1 S152 S160.
14. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 (23 2839 2848.
15. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004 351 (5 451 459.
16. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004 18 (13 F27 F36.
17. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 (5 438 450.
18. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 : 986 992.
19. Kaul V, Friedenberg FK, Braitman LE et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002 97 (10 2623 2628.
20. Le Calvez S, Thabut D, Messous D et al. The predictive value of Fibrotest vs APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004 39 (3 862 863.
21. Thabut D, Simon M, Myers RP et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003 37 (5 1220 1221.
22. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 (2 518 526.
23. Fortunato G, Castaldo G, Oriani G et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001 47 (9 1696 1700.
24. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 (9262 1069 1075.
25. Leroy V, Monier F, Bottari S et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004 99 (2 271 279.
26. Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004 41 (6 935 942.
27. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004 127 (6 1704 1713.
28. Sud A, Hui JM, Farrell GC et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004 39 (5 1239 1247.
29. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003 29 (12 1705 1713.
30. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 (2 343 350.
31. Myers RP, Benhamou Y, Imbert-Bismut F et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003 17 (5 721 725.
32. Kelleher TB, Mehta SH, Bhaskar R et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005 43 (1 78 84.
33. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43 (6 1317 1325.
34. de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006 41 (2 175 179.
35. Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn 2004 4 (5 715 726.
36. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 2005 100 (9 1981 1983.
37. Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol 2005 43 (1 2 5.
38. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006 44 (3 462 474.
39. Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci 1989 34 (3 322 323.
40. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 (2 289 293.
41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 (3 837 845.
42. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 (3 839 843.
43. Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 (3 636 641.
44. Negro F. Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol 2006 45 (4 514 519.
45. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003 125 (6 1695 1704.
46. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003 39 (6 1049 1055.
47. Hickman IJ, Powell EE, Prins JB et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003 39 (6 1042 1048.
48. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 (3 840 848.